GDTC (CytoMed) Forward P/E Multiple
The forward P/E ratio of CytoMed Therapeutics (GDTC) exhibits volatility, with the metric currently standing at 0.00. This price action is driven by early-stage immunotherapy trials and capital expenditures. Growth is supported by the optimization of cryogenic logistics to preserve margins and a strategic alliance with hospitals for the treatment of intestinal and liver tumors using the T-cell method.
Summary analytical data breakdowns for CytoMed (GDTC)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital CytoMed Therapeutics|GDTC - Long-Term Liabilities to Capital|Short-Term Debt to Capital CytoMed Therapeutics|GDTC - Company Total Debt|Debt to Book Value CytoMed Therapeutics Ltd|GDTC - Long-Term Debt|Company Current Liabilities CytoMed Therapeutics|Quick Liquidity w2.cytomed.sg
- financial results and valuation multiples details:
GDTC - Company Net Income|Expected Profit CytoMed Therapeutics|GDTC - Price to Earnings Ratio|Forward P/E Multiple CytoMed Therapeutics|GDTC - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple CytoMed Therapeutics Ltd|GDTC - Operating profit before amortization|Net earnings per share for the last 12 months CytoMed Therapeutics|GDTC - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months w2.cytomed.sg|GDTC - Net earnings per one share growth for the current year|Earnings growth forecast for next year CytoMed Therapeutics
- sales volume and revenue indicators:
Fundamental company analysis:CytoMed Therapeutics Limited GDTC
Fundamental valuation via forward P/E minimizes risks by comparing the current share price of CytoMed Therapeutics (GDTC) with projected earnings from the implementation of donor CAR-T therapies in oncology centers. Analyzing changes in the company's expected P/E allows for a determination of the extent to which the market has priced in future insurance payouts, assessing the effectiveness of business capitalization through the ratio of market value to expected earnings.
Competitors of CytoMed Therapeutics (GDTC)
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Projected Price to Earnings aurabiosciences.com AURA|Candel Therapeutics, Inc. - Projected Price to Earnings|Accuray Inc (ARAY) - Projected Price to Earnings Ratio|SLS: Projected Price to Earnings|Actuate Therapeutics Inc - Market Cap to Future Earnings Ratio|Citius Oncology, Inc. (CTOR) - Future Price to Earnings|Projected Price to Earnings Ratio TuHURA Biosciences (HURA)|Future Price to Earnings Protara Therapeutics, Inc.|Projected Price to Earnings Fate Therapeutics Inc (FATE)|Forward P/E Multiple WHWK|TCRX - Projected Price to Earnings Ratio|Forward P/E Multiple CSBR (Champions Oncology, Inc.)|XBIT: Price to Future Earnings Ratio|CVM: Projected Price to Earnings|Future Price to Earnings Multiple OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Projected Price to Earnings|ARTV: Market Cap to Future Earnings Ratio|ANL (Adlai Nortye Ltd) - Forward P/E Multiple|VERU: Future Price to Earnings Multiple|Forward P/E Multiple TPST|XLO - Projected Price to Earnings Ratio|Future Price to Earnings Renovaro RENB|Future Price to Earnings Multiple MURA|Kairos Pharma Inc - Forward P/E Multiple|OKUR - Forward P/E Multiple|curis.com (CRIS) - Future Price to Earnings|Price to Expected Earnings Ratio APLM (Apollomics)|THAR (Tharimmune Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Advanced Biomed Corp ADVB|Projected Price to Earnings GNPX (Genprex, Inc.)|Forward P/E Multiple calidibio.com (CLDI)|Sunshine Biopharma, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio XBIO (Xenetic Biosciences Inc.)|Salarius - Forward P/E Multiple|Market Cap to Projected Earnings Kitov Pharma PPBT|AONC: Forward P/E Multiple|Projected Price to Earnings beigene.com|Future Price to Earnings Checkpoint Therapeutics, Inc.|elevationoncology.com (ELEV) - Market Cap to Projected Earnings|Forward P/E Multiple ICAD|ikenaoncology.com (IKNA) - Forward Price to Earnings Multiple|Forward P/E Multiple NTBL (Notable Labs, Ltd.)|VIRX: Price to Future Earnings Ratio|MOR: Projected Price to Earnings|NAYA Biosciences Inc - Market Cap to Future Earnings Ratio|AAPGV: Forward P/E Multiple
